Zynerba Pharmaceuticals (ZYNE) Prices 3M Common Stock IPO at $14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Zynerba Pharmaceuticals (ZYNE) IPO Opens Up 29% Higher
August 5, 2015 10:54 AM EDTToday's IPO for Zynerba Pharmaceuticals (NASDAQ: ZYNE) opened for trading at $18 after pricing 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the... More
